Literature DB >> 11657673

Conflicts of interest: research and clinical care.

John C Morris1.   

Abstract

Conflicts of interest and other ethical dilemmas occur in Alzheimer disease (AD) patient care and research but often are underrecognized by physicians. One or more bioethical principles of autonomy, confidentiality, truth telling, beneficence, and justice, which apply to demented individuals as they do to other patients, may conflict in everyday clinical situations. For example, when demented patients wish to continue driving, autonomy (the patient's right to self-determination) conflicts with beneficence (the duty to promote the patient's welfare). Cognitively impaired patients depend on others for ethical decision making in the resolution of these dilemmas. It is essential that clinicians and investigators involved in the decision-making process do so without bias or conflict of interest. Full disclosure of financial interests increasingly is an accepted requirement in the conduct of biomedical research. In AD, less obvious potential conflicts of interest arise when physicians recruit their patients for antidementia drug trials sponsored by a pharmaceutical company (that provides the physician with research funding) or when investigators fail to acknowledge the patient's withdrawal of assent when attempting to complete a research protocol. The recognition of both financial and nonfinancial conflicts should lead to measures to reduce bias, which in turn will improve the integrity of research findings and promote patient welfare.

Entities:  

Keywords:  Biomedical and Behavioral Research; Mental Health Therapies; Professional Patient Relationship

Mesh:

Substances:

Year:  1994        PMID: 11657673

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  1 in total

1.  Financial capacity in persons with schizophrenia and serious mental illness: clinical and research ethics aspects.

Authors:  Daniel C Marson; Robert Savage; Jacqueline Phillips
Journal:  Schizophr Bull       Date:  2005-11-17       Impact factor: 9.306

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.